JP2013512915A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512915A5
JP2013512915A5 JP2012542178A JP2012542178A JP2013512915A5 JP 2013512915 A5 JP2013512915 A5 JP 2013512915A5 JP 2012542178 A JP2012542178 A JP 2012542178A JP 2012542178 A JP2012542178 A JP 2012542178A JP 2013512915 A5 JP2013512915 A5 JP 2013512915A5
Authority
JP
Japan
Prior art keywords
independently
compound according
alkyl
cycloalkyl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512915A (ja
JP5753185B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/058672 external-priority patent/WO2011068941A2/en
Publication of JP2013512915A publication Critical patent/JP2013512915A/ja
Publication of JP2013512915A5 publication Critical patent/JP2013512915A5/ja
Application granted granted Critical
Publication of JP5753185B2 publication Critical patent/JP5753185B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542178A 2009-12-04 2010-12-02 プロリン誘導体 Expired - Fee Related JP5753185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26658409P 2009-12-04 2009-12-04
US61/266,584 2009-12-04
PCT/US2010/058672 WO2011068941A2 (en) 2009-12-04 2010-12-02 Proline derivatives

Publications (3)

Publication Number Publication Date
JP2013512915A JP2013512915A (ja) 2013-04-18
JP2013512915A5 true JP2013512915A5 (enExample) 2014-01-23
JP5753185B2 JP5753185B2 (ja) 2015-07-22

Family

ID=44082623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542178A Expired - Fee Related JP5753185B2 (ja) 2009-12-04 2010-12-02 プロリン誘導体

Country Status (10)

Country Link
US (1) US8415482B2 (enExample)
EP (1) EP2507232B1 (enExample)
JP (1) JP5753185B2 (enExample)
KR (1) KR101768946B1 (enExample)
CN (1) CN102482269B (enExample)
AU (1) AU2010325980B2 (enExample)
CA (1) CA2781140C (enExample)
MY (1) MY179840A (enExample)
TW (1) TWI429645B (enExample)
WO (1) WO2011068941A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
MX2011006333A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA118080C2 (uk) * 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105228619B (zh) * 2012-11-08 2019-05-24 财团法人国家卫生研究院 治疗c型肝炎病毒感染的医药组合物
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104774194B (zh) * 2014-01-09 2018-01-30 正大天晴药业集团股份有限公司 氘代的丙型肝炎病毒抑制剂
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用
CN118019739A (zh) 2021-08-25 2024-05-10 皮克医疗公司 Eif4e抑制剂及其用途
CN113861061A (zh) * 2021-10-25 2021-12-31 成都市科隆化学品有限公司 一种不含无机铵盐的氨基酸酰胺盐酸盐及其合成方法
TW202432552A (zh) * 2022-10-28 2024-08-16 法國國家健康及醫學研究中心 磷脂醯肌醇3-激酶的新穎抑制劑
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043545A1 (en) * 2001-11-02 2005-02-24 Gianpalol Bravi 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
KR20180028070A (ko) * 2009-05-13 2018-03-15 길리애드 파마셋 엘엘씨 항바이러스 화합물
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Similar Documents

Publication Publication Date Title
JP2013512915A5 (enExample)
JP2011522789A5 (enExample)
JP2010511721A5 (enExample)
JP2012515776A5 (enExample)
JP2013537203A5 (enExample)
JP2012092103A5 (enExample)
JP2015534574A5 (enExample)
JP2015502963A5 (enExample)
JP2007523139A5 (enExample)
EA200901241A1 (ru) Соединения для лечения гепатита с
JP2016503799A5 (enExample)
JP2012526168A5 (enExample)
JP2016537368A5 (enExample)
JP2011513410A5 (enExample)
JP2014528467A5 (enExample)
JP2013129675A5 (enExample)
JP2011523411A5 (enExample)
JP2011079828A5 (enExample)
JP2015143283A5 (enExample)
JP2010504286A5 (enExample)
JP2011219498A5 (enExample)
JP2010527913A5 (enExample)
JP2016505614A5 (enExample)
JP2011227454A5 (enExample)
JP2014063155A5 (enExample)